Effects of Docetaxel and Abiraterone Acetate on Nrf2 Expression in Androgen-Sensitive and Androgen-Insensitive Prostate Cancer Cells

Purpose

Docetaxel and Abiraterone acetate are the drugs of choice, especially for cases of prostate cancer that are insensitive to androgen deprivation therapy. Nrf2, which has antioxidative properties in normal cells, also protects cancer cells from apoptosis, causing the cells to be unresponsive to treatment. This study aimed to investigate the effect of Docetaxel and Abiraterone acetate administration to human prostate cancer cells on Nrf2 expression in vitro. Materials and Methods: Two different prostate cancer cell lines were used: androgen-responsive and non-androgen-responsive. 4 groups were formed as control, AA (Abiraterone Acetate), DTX (Docetaxel), and AA+DTX. Cells were cultured with abiraterone acetate and Docetaxel for 72 hours. Then, Nrf2 expression changes were examined by immunofluorescence and Western blot methods.